Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-520 of 100 mg daily CAMBRIDGE, Mass., Sept. 5, 2023 /PRNewswire/ -- Nuvalent, Inc. (NUVL) (Nasdaq: NUVL), a ...
Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...
Roman Kniazev, CEO of Nuravax, Inc., said, "The MultiTEP platform behind AV-1959R was specifically engineered to overcome immunological tolerance and safely induce strong anti-Aβ antibody responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback